Danaher (NYSE:DHR)‘s stock had its “buy” rating restated by equities research analysts at Robert W. Baird in a research report issued on Friday. They currently have a $99.00 price objective on the conglomerate’s stock. Robert W. Baird’s price objective points to a potential upside of 5.32% from the stock’s current price.
Several other brokerages also recently issued reports on DHR. Citigroup raised their price objective on shares of Danaher to $107.00 and gave the stock a “buy” rating in a research note on Friday. Goldman Sachs Group restated a “neutral” rating and issued a $83.00 price objective on shares of Danaher in a research note on Tuesday, September 26th. Credit Suisse Group raised their price objective on shares of Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. J P Morgan Chase & Co restated an “overweight” rating and issued a $95.00 price objective on shares of Danaher in a research note on Friday, September 8th. Finally, Morgan Stanley raised their price objective on shares of Danaher from $95.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $94.18.
Shares of Danaher (NYSE:DHR) traded up $1.15 during mid-day trading on Friday, reaching $94.00. The company’s stock had a trading volume of 5,071,100 shares, compared to its average volume of 2,627,007. Danaher has a one year low of $77.66 and a one year high of $94.82. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. The firm has a market capitalization of $65,386.87, a P/E ratio of 24.16, a PEG ratio of 2.24 and a beta of 1.02.
In other Danaher news, Director Donald J. Ehrlich sold 10,578 shares of Danaher stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the transaction, the director now directly owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Daniel L. Comas sold 88,184 shares of Danaher stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total value of $8,026,507.68. Following the transaction, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at $20,735,812.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 273,810 shares of company stock valued at $25,218,813. 12.20% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of DHR. National Asset Management Inc. raised its holdings in shares of Danaher by 33.7% in the first quarter. National Asset Management Inc. now owns 3,753 shares of the conglomerate’s stock valued at $321,000 after buying an additional 947 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in Danaher in the first quarter worth about $465,000. Fiduciary Trust Co. increased its position in Danaher by 1.1% in the first quarter. Fiduciary Trust Co. now owns 11,756 shares of the conglomerate’s stock worth $1,005,000 after purchasing an additional 123 shares during the period. Caxton Associates LP acquired a new stake in Danaher in the first quarter worth about $624,000. Finally, Flagship Harbor Advisors LLC increased its position in Danaher by 36.1% in the first quarter. Flagship Harbor Advisors LLC now owns 6,632 shares of the conglomerate’s stock worth $571,000 after purchasing an additional 1,758 shares during the period. 76.32% of the stock is owned by institutional investors.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.